Scholar Response
Response Fields
| Field | Type | Description | Example |
|---|---|---|---|
| patent_citations | Array of Patent Citation | Referenced by patents | |
| patent_citations_count | Integer | Number of patent citations | 10 |
| lens_id | String | Unique lens identifier | 100-004-910-081-14X |
| created | Date | Record created date | 2016-08-01T00:00:00+00:00 |
| publication_type | String | Publication Type | journal article |
| publication_supplementary_type | Array of String | Supplementary publication type | ["review"] |
| authors | Array of Author | Authors | |
| title | String | Title of the scholarly work | Malaria |
| external_ids | Array of Ids | The external identifier(s) for a scholarly work (DOI, PubMed ID, PubMed Central ID, Microsoft Academic ID or CORE) | |
| start_page | String | Start page | 893 |
| end_page | String | End page | 916 |
| volume | String | Volume | 32 |
| issue | String | Issue | 4 |
| languages | Array of String | Languages | ["ENG"] |
| references | List of Reference | References | |
| scholarly_citations | List of Lens Ids | Scholarly Citations | ["091-720-300-990-437"] |
| chemicals | List of Chemical | Chemicals | |
| clinical_trials | List of Clinical Trial | Clinical Trials | |
| fields_of_study | List of String | Fields Of Study | ["Immunology", "Malaria"] |
| source_urls | List of Source URL | Source Urls | |
| abstract | String | Scholarly work abstract text | |
| date_published | Date | Date of publication | 2009-05-22 |
| date_published_parts | Array of Integer | Consist of year, month and day | [1974, 1, 6] |
| year_published | Integer | Year of publication | 1986 |
| conference | Conference | The conference instance or edition | |
| author_count | Integer | Number of Authors | 4 |
| references_count | Integer | The number of works in the reference list of a scholarly work | 2 |
| scholarly_citations_count | Integer | The number of scholarly works that cite this scholarly work | 3 |
| open_access | Open Access | ||
| source | Source | Source publication in which the scholarly work appears | |
| keywords | Array of String | Keywords | |
| mesh_terms | Array of MeSH Term | MeSH term | |
| funding | Array of Funding | Funding |
Patent Citation
| Field | Type | Description | Example |
|---|---|---|---|
| lens_id | String | Unique lens identifier | 141-171-521-309-804 |
Author
| Field | Type | Description | Example |
|---|---|---|---|
| collective_name | String | Author Collective Name | |
| first_name | String | The author’s first name | Alexander |
| last_name | String | The author’s last name | Kupco |
| initials | String | Author Initials | A |
| affiliations | Array of Affiliation | The institution/affiliations associated with Author. | |
| ids | Array of Ids | Author’s MAG, ORCID identifiers | [{"type": "magid", "value": "1234567890"}] |
Affiliation
| Field | Type | Description | Example |
|---|---|---|---|
| name | String | The institution associated with the author affiliations. | Stony Brook University |
| grid_id | String | Affiliation grid id | grid.9018.0 |
| country_code | String | Comma separated country codes | DE |
| ids | Array of Ids | The external institution identifiers associated with the author’s affiliation |
Reference
| Field | Type | Description | Example |
|---|---|---|---|
| lens_id | String | Unique lens identifier | 071-957-228-698-625 |
Open Access
| Field | Type | Description | Example |
|---|---|---|---|
| license | String | The Open Access license type | cc-by |
| colour | String | The Open Access colour category | gold |
Source
| Field | Type | Description | Example |
|---|---|---|---|
| title | String | The name of source publication in which the scholarly work appears | Journal name, Book title, Confernce proceedings |
| type | String | Source Type | Journal |
| publisher | String | The publisher of the source publication | W.B. Saunders Ltd |
| issn | Array of Object | ISSN | [{"value": "10797114"}] |
| country | String | The publisher’s country | United Kingdom |
| asjc_codes | String | The All Science Journal Classification (ASJC) code | 2735 |
| asjc_subjects | String | Subject is derived from journals descriptions in Crossref metadata based on the Science Journal Classification Codes | Pediatrics |
Mesh Term
| Field | Type | Description | Example |
|---|---|---|---|
| mesh_id | String | MeSH term unique identifier. MeSH terms are the National Library of Medicine’s controlled vocabulary or subject heading list. | D000293 |
| mesh_heading | String | MeSH terms are the National Library of Medicine’s controlled vocabulary or medical subject headings assigned to PubMed entries. NB MeSH Headings are case sensitive. | Adolescent |
| qualifier_id | String | Mesh Term Qualifier ID | Q000032 |
| qualifier_name | String | Mesh Term Qualifier Name | analysis |
ISSN
| Field | Type | Description | Example |
|---|---|---|---|
| value | String | The International Standard Serial Number | 10797114 |
| type | String | ISSN type | print, electronic |
Funding
| Field | Type | Description | Example |
|---|---|---|---|
| org | String | Name of the funding organisation | NIDCR NIH HHS |
| funding_id | String | The funding organisation’s project identifier | U01 DE018902 |
| country | String | The country of the funding body | United States |
Conference
| Field | Type | Description | Example |
|---|---|---|---|
| name | String | Conference Name | International Electron Devices Meeting |
| instance | String | Conference Instance Name | CHI 1985 |
| location | String | The location of the conference | Lihue, Kauai, HA, USA |
Chemical
| Field | Type | Description | Example |
|---|---|---|---|
| mesh_id | String | MeSH term id | D000293 |
| registry_number | String | Chemical registration number | 5Q7ZVV76EI |
| substance_name | String | Substance name | Antimalarials |
Clinical Trial
| Field | Type | Description | Example |
|---|---|---|---|
| id | String | Identifier | nct00105716 |
| registry | String | Clinical Trial Registry | 10.18810/clinical-trials-gov |
Source URL
| Field | Type | Description | Example |
|---|---|---|---|
| type | String | Source URL Type | html |
| url | String | URL String | http://cds.cern.ch/record/2291692 |
Ids
| Field | Type | Description | Example |
|---|---|---|---|
| type | String | The type/s of external identifiers for the scholarly work, author, institution, etc. | doi, pmid, magid, orcid, grid, ror, etc. |
| value | String | The external identifier(s) for the scholarly work, author, institution, etc. | 10.1016/s0031-3955(16)34861-1, 0000-0003-3902-2234, grid.425957.8, https://ror.org/056x7d368, etc. |
Sample API Response
Request:
{
"query":{
"match":{"lens_id":"086-713-276-176-892"}
}
}
Response:
{
"total": 1,
"data": [
{
"patent_citations": [
{
"lens_id": "122-064-734-901-067"
}
],
"patent_citations_count": 1,
"lens_id": "086-713-276-176-892",
"created": "2018-05-12T02:39:28.395000+00:00",
"open_access": {
"license": "cc-by-nc-nd",
"colour": "hybrid"
},
"publication_type": "journal article",
"publication_supplementary_type": [
"clinical trial, phase ii",
"multicenter study",
"randomized controlled trial",
"research support, non-u.s. gov't"
],
"authors": [
{
"collective_name": null,
"first_name": "Maha",
"last_name": "Hussain",
"initials": "M",
"affiliations": [
{
"name": "University of Michigan",
"grid_id": "grid.214458.e",
"country_code": "US"
}
]
},
{
"collective_name": null,
"first_name": "Dana E.",
"last_name": "Rathkopf",
"initials": "DE",
"affiliations": [
{
"name": "Memorial Sloan Kettering Cancer Center",
"grid_id": "grid.51462.34",
"country_code": "US"
}
]
},
{
"collective_name": null,
"first_name": "Glenn",
"last_name": "Liu",
"initials": "G",
"affiliations": [
{
"name": "University of Wisconsin-Madison",
"grid_id": "grid.14003.36",
"country_code": "US"
}
]
},
{
"collective_name": null,
"first_name": "Andrew J.",
"last_name": "Armstrong",
"initials": "AJ",
"affiliations": [
{
"name": "Duke University",
"grid_id": "grid.26009.3d",
"country_code": "US"
}
]
},
{
"collective_name": null,
"first_name": "Kevin",
"last_name": "Kelly",
"initials": "K",
"affiliations": [
{
"name": "Thomas Jefferson University",
"grid_id": "grid.265008.9",
"country_code": "US"
}
]
},
{
"collective_name": null,
"first_name": "Anna C.",
"last_name": "Ferrari",
"initials": "AC",
"affiliations": [
{
"name": "New York University",
"grid_id": "grid.137628.9",
"country_code": "US"
}
]
},
{
"collective_name": null,
"first_name": "John D.",
"last_name": "Hainsworth",
"initials": "JD",
"affiliations": [
{
"name": "Sarah Cannon Research Institute",
"grid_id": "grid.477834.b",
"country_code": "GB"
}
]
},
{
"collective_name": null,
"first_name": "Adarsh",
"last_name": "Joshi",
"initials": "A",
"affiliations": [
{
"name": "Eli Lilly and Company",
"grid_id": "grid.488258.b",
"country_code": "IT"
}
]
},
{
"collective_name": null,
"first_name": "Rebecca R.",
"last_name": "Hozak",
"initials": "RR",
"affiliations": [
{
"name": "Eli Lilly and Company",
"grid_id": "grid.488258.b",
"country_code": "IT"
}
]
},
{
"collective_name": null,
"first_name": "Ling",
"last_name": "Yang",
"initials": "L",
"affiliations": [
{
"name": "Eli Lilly and Company",
"grid_id": "grid.488258.b",
"country_code": "IT"
}
]
},
{
"collective_name": null,
"first_name": "Jonathan D.",
"last_name": "Schwartz",
"initials": "JD",
"affiliations": [
{
"name": "Eli Lilly and Company",
"grid_id": "grid.488258.b",
"country_code": "IT"
}
]
},
{
"collective_name": null,
"first_name": "Celestia S.",
"last_name": "Higano",
"initials": "CS",
"affiliations": [
{
"name": "University of Washington",
"grid_id": "grid.34477.33",
"country_code": "US"
}
]
}
],
"title": "A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer",
"volume": "51",
"issue": "13",
"languages": [
"en"
],
"references": [
{
"lens_id": "003-415-704-045-340"
},
{
"lens_id": "006-027-163-131-418"
},
{
"lens_id": "007-652-362-542-447"
},
{
"lens_id": "010-839-632-959-305"
},
{
"lens_id": "013-690-046-069-453"
},
{
"lens_id": "015-449-984-502-884"
},
{
"lens_id": "015-767-931-570-158"
},
{
"lens_id": "018-245-327-947-052"
},
{
"lens_id": "020-963-415-260-304"
},
{
"lens_id": "026-332-934-265-841"
},
{
"lens_id": "028-101-820-366-93X"
},
{
"lens_id": "032-523-762-689-478"
},
{
"lens_id": "037-117-740-052-570"
},
{
"lens_id": "038-557-040-762-884"
},
{
"lens_id": "040-239-601-782-040"
},
{
"lens_id": "042-246-996-698-043"
},
{
"lens_id": "043-024-349-674-734"
},
{
"lens_id": "043-201-312-439-671"
},
{
"lens_id": "046-041-414-632-674"
},
{
"lens_id": "046-648-350-541-685"
},
{
"lens_id": "046-852-526-558-260"
},
{
"lens_id": "054-808-246-993-497"
},
{
"lens_id": "059-727-763-246-876"
},
{
"lens_id": "065-982-455-260-233"
},
{
"lens_id": "069-612-901-254-771"
},
{
"lens_id": "070-794-057-102-152"
},
{
"lens_id": "083-233-359-584-62X"
},
{
"lens_id": "087-375-055-670-659"
},
{
"lens_id": "087-458-139-690-01X"
},
{
"lens_id": "090-234-280-758-859"
},
{
"lens_id": "094-489-992-059-749"
},
{
"lens_id": "095-400-716-937-253"
},
{
"lens_id": "096-654-301-744-608"
},
{
"lens_id": "101-625-667-760-940"
},
{
"lens_id": "113-073-836-369-700"
},
{
"lens_id": "128-335-721-572-401"
},
{
"lens_id": "155-152-241-876-905"
}
],
"keywords": [
"Cixutumumab",
"Mitoxantrone",
"Prednisone",
"Prostate cancer",
"Ramucirumab"
],
"mesh_terms": [
{
"mesh_heading": "Adenocarcinoma",
"qualifier_name": "drug therapy",
"mesh_id": "D000230",
"qualifier_id": "Q000188"
},
{
"mesh_heading": "Adolescent",
"mesh_id": "D000293"
},
{
"mesh_heading": "Adult",
"mesh_id": "D000328"
},
{
"mesh_heading": "Aged",
"mesh_id": "D000368"
},
{
"mesh_heading": "Antibodies, Monoclonal",
"qualifier_name": "administration & dosage",
"mesh_id": "D000911",
"qualifier_id": "Q000008"
},
{
"mesh_heading": "Antineoplastic Combined Chemotherapy Protocols",
"qualifier_name": "adverse effects",
"mesh_id": "D000971",
"qualifier_id": "Q000009"
},
{
"mesh_heading": "Disease Progression",
"mesh_id": "D018450"
},
{
"mesh_heading": "Disease-Free Survival",
"mesh_id": "D018572"
},
{
"mesh_heading": "Docetaxel",
"mesh_id": "D000077143"
},
{
"mesh_heading": "Humans",
"mesh_id": "D006801"
},
{
"mesh_heading": "Kaplan-Meier Estimate",
"mesh_id": "D053208"
},
{
"mesh_heading": "Male",
"mesh_id": "D008297"
},
{
"mesh_heading": "Middle Aged",
"mesh_id": "D008875"
},
{
"mesh_heading": "Mitoxantrone",
"qualifier_name": "administration & dosage",
"mesh_id": "D008942",
"qualifier_id": "Q000008"
},
{
"mesh_heading": "Prednisone",
"qualifier_name": "administration & dosage",
"mesh_id": "D011241",
"qualifier_id": "Q000008"
},
{
"mesh_heading": "Proportional Hazards Models",
"mesh_id": "D016016"
},
{
"mesh_heading": "Prostatic Neoplasms, Castration-Resistant",
"qualifier_name": "drug therapy",
"mesh_id": "D064129",
"qualifier_id": "Q000188"
},
{
"mesh_heading": "Taxoids",
"qualifier_name": "therapeutic use",
"mesh_id": "D043823",
"qualifier_id": "Q000627"
},
{
"mesh_heading": "Time Factors",
"mesh_id": "D013997"
},
{
"mesh_heading": "Treatment Outcome",
"mesh_id": "D016896"
},
{
"mesh_heading": "United States",
"mesh_id": "D014481"
},
{
"mesh_heading": "Young Adult",
"mesh_id": "D055815"
}
],
"chemicals": [
{
"substance_name": "Antibodies, Monoclonal",
"registry_number": "0",
"mesh_id": "D000911"
},
{
"substance_name": "Taxoids",
"registry_number": "0",
"mesh_id": "D043823"
},
{
"substance_name": "anti-IGF-1R antibody A12",
"registry_number": "0",
"mesh_id": "C557414"
},
{
"substance_name": "Docetaxel",
"registry_number": "15H5577CQD",
"mesh_id": "D000077143"
},
{
"substance_name": "Mitoxantrone",
"registry_number": "BZ114NVM5P",
"mesh_id": "D008942"
},
{
"substance_name": "ramucirumab",
"registry_number": "D99YVK4L0X",
"mesh_id": "C543333"
},
{
"substance_name": "Prednisone",
"registry_number": "VB0R961HZT",
"mesh_id": "D011241"
}
],
"clinical_trials": [
{
"id": "nct00683475",
"registry": "10.18810/clinical-trials-gov"
}
],
"fields_of_study": [
"M.2",
"Immunology",
"Cixutumumab",
"Prednisone",
"Ramucirumab",
"Prostate cancer",
"Mitoxantrone",
"Docetaxel",
"Regimen",
"Medicine"
],
"funding": [
{
"org": "NCI NIH HHS",
"funding_id": "P30 CA008748",
"country": "United States"
}
],
"source_urls": [
{
"type": "unknown",
"url": "http://www.ejcancer.com/article/S0959-8049(15)00450-5/pdf"
},
{
"type": "html",
"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024789/"
},
{
"type": "html",
"url": "https://www.scholars.northwestern.edu/en/publications/a-randomised-non-comparative-phase-ii-trial-of-cixutumumab-imc-a1"
},
{
"type": "html",
"url": "https://www.sciencedirect.com/science/article/pii/S0959804915004505"
},
{
"type": "core_fulltext",
"url": "https://core.ac.uk/download/pdf/82196673.pdf"
}
],
"abstract": "Abstract Background Cixutumumab, a human monoclonal antibody (HuMAb), targets the insulin-like growth factor receptor. Ramucirumab is a recombinant HuMAb that binds to vascular endothelial growth factor receptor-2. A non-comparative randomised phase II study evaluated cixutumumab or ramucirumab plus mitoxantrone and prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC). Patients and methods Men with progressive mCRPC during or after docetaxel therapy received mitoxantrone 12 mg/m 2 on day 1 and prednisone 5 mg twice daily and were randomised 1:1 to receive either cixutumumab or ramucirumab 6 mg/kg intravenously weekly in a 21-day cycle. Primary end-point was composite progression-free survival (cPFS). Secondary end-points included safety, response, radiographic progression-free survival (PFS) and overall survival (OS). Sample size was based on a 50% increase in median cPFS from 2.6 (MP) to 3.9 months (either combination). Results 132 men were treated (66 per arm). Median cPFS was 4.1 months (95% confidence interval (CI), 2.2–5.6) for cixutumumab and 6.7 months (95% CI, 4.5–8.3) for ramucirumab. Median time to radiographic progression was 7.5 months for cixutumumab and 10.2 months for ramucirumab, with a median OS of 10.8 and 13.0 months, respectively. Fatigue was the most frequent adverse event (AE). Incidence of most non-haematologic grade 3–4 AEs was Conclusion Combinations of cixutumumab or ramucirumab plus MP were feasible and associated with moderate toxicities in docetaxel-pretreated men with mCRPC. Of the two regimens, the ramucirumab regimen is worthy of further testing based on the observed cPFS relative to the historical control.",
"year_published": 2015,
"references_count": 37,
"scholarly_citations_count": 10,
"external_ids": [
{
"type": "magid",
"value": "2113210954"
},
{
"type": "pmid",
"value": "26082390"
},
{
"type": "doi",
"value": "10.1016/j.ejca.2015.05.019"
}
],
"start_page": "1714",
"end_page": "1724",
"source": {
"title": "European Journal of Cancer",
"type": "Journal",
"publisher": "Elsevier BV",
"issn": [
{
"value": "09598049"
}
],
"country": "United Kingdom",
"asjc_codes": [
"1306",
"2730"
],
"asjc_subjects": [
"Oncology",
"Cancer Research"
]
},
"scholarly_citations": [
"000-201-187-558-654",
"026-107-871-228-662",
"028-262-672-178-175",
"030-115-779-382-725",
"035-630-845-016-108",
"037-016-998-061-439",
"062-343-220-167-149",
"067-043-485-486-441",
"145-126-752-104-913",
"174-636-795-252-301"
],
"author_count": 12,
"date_published": "2015-06-13T00:00:00+00:00"
}
],
"results": 1
}